Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332268 | 0.82 | ALOX5 (0.57) | ALOX5PIK3CDHRH3P2RX7 | |
| SCHEMBL332784 | 0.82 | ALOX5 (0.53) | ALOX5PIK3CDHRH3PTGDR | |
| SCHEMBL13807413 | 0.81 | ALOX5 (0.51) | ALOX5PIK3CDHRH3OPRL1 | |
| SCHEMBL332895 | 0.81 | ALOX5 (0.53) | ALOX5PIK3CDHRH3 | |
| SCHEMBL333542 | 0.79 | ALOX5 (0.56) | ALOX5PIK3CDITGB2ICAM1ITGAL | |
| SCHEMBL7654887 | 0.78 | ALOX5 (0.68) | ALOX5PIK3CDHRH3OPRL1HDAC1 | |
| SCHEMBL332613 | 0.77 | ALOX5 (0.62) | ALOX5PIK3CDHRH3P2RX7 | |
| SCHEMBL332226 | 0.76 | ALOX5 (0.66) | ALOX5PIK3CDHRH3HDAC1 | |
| SCHEMBL13201380 | 0.75 | ALOX5 (0.58) | ALOX5PIK3CDHRH3 | |
| SCHEMBL332599 | 0.75 | ALOX5 (0.55) | ALOX5PIK3CDHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | ALOX5 1/4885PIK3CD 1305/4885MAP4K4 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.